Penny stock picks | research with support and resistance for trading | stock investing
day investing picks penny stock trading
Skip Navigation Links
    Home
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event
    Login


Join Now




Advertise 2 my advertising 3 of 5
 

NEKTAR THERAPEUTICS COM support, resistance research

Stock : NKTR |   Stock Recommendations : Buy
Sector : Medical Equipment & Supplies |   First resistance : 7.26
Stock Name : NEKTAR THERAPEUTICS COM |   Second resistance : 13.15
Buy Near : 5.53 |   Third resistance : 17.00
StopLoss : 3.64 |   First Support : 3.64
Posted date : 11/2/2008 12:00:00 AM |   Second Support : 2.91


Nektar Therapeutics com (NKTR) given a nice double top breakout on 10/31/08 with good volume. Again many technical indicators also have given a buy signal, with

   rising moving average weekly and daily Stockhastic given a buy signal and ADX also given a buy signal. Nektar Therapeutics com (NKTR) reported positive Phase 1 data for its lead proprietary oncology product candidate, NKTR-102. As per technical indicator analysis this Stock looks good candidate for portfolio investment and also for day trading, Stock investing, trend trading | swing trading. Due to Stock market and economic condition keep tight stop loss on all position. Buy with our first target $7.26 and keep stop loss $3.64



Penny Stocks



Recent News Head Lines
Nektar (NKTR) Down 12% Since Last Earnings Report: Can It Rebound?
(Sat, 05 Sep 2020 15:32:03 +0000)
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Did Hedge Funds Make The Right Call On Nektar Therapeutics (NKTR) ?
(Wed, 12 Aug 2020 13:42:35 +0000)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck
(Wed, 12 Aug 2020 12:00:00 +0000)
Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) today announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar's CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
(Fri, 07 Aug 2020 15:35:03 +0000)
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
(Thu, 06 Aug 2020 23:00:11 +0000)
Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?


Never go against major trend for Penny stock trading | investing
  


Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006 Flyingstock.com
Chart courtesy of StockCharts.com
Penny stock trading- NEKTAR THERAPEUTICS COM for penny stock investing Day Trading

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.